HuGE Literature Finder
Records
1
-
17
| Influence of CYP2D6 Polymorphism on the Pharmacokinetic/Pharmacodynamic Characteristics of Carvedilol in Healthy Korean Volunteers. Journal of Korean medical science 2018 Jul 33 (27): e182. Jung Eben, Ryu Sunae, Park Zewon, Lee Jong-Gu, Yi Jung-Yeon, Seo Doo Won, Lee Juhyun, Jeong Ho-Sang, Kim Jeong Mi, Oh Woo-Yo |
| The Association of ADRB1 and CYP2D6 Polymorphisms With Antihypertensive Effects and Analysis of Their Contribution to Hypertension Risk. The American journal of the medical sciences 2018 Mar 355 (3): 235-239. Chen Liping, Xiao Ting, Chen Liling, Xie Shanshan, Deng Maoqing, Wu Dingcha |
| Polymorphisms in CYP450 Genes and the Therapeutic Effect of Atorvastatin on Ischemic Stroke: A Retrospective Cohort Study in Chinese Population. Clinical therapeutics 2018 Feb . Peng Chen, Ding Ying, Yi Xin, Shen Yupei, Dong Zhiqiang, Cao Limei, Li Qiang, Ren Haiyan, He Lin, Zhou Daizhan, Chen |
| Pharmacogenetics of Vascular Risk Factors in Alzheimer's Disease. Journal of personalized medicine 2018 Jan 8 (1): . Cacabelos Ramón, Meyyazhagan Arun, Carril Juan C, Cacabelos Pablo, Teijido Ósc |
| Multiple adverse drug reactions and genetic polymorphism testing: A case report with negative result. Medicine 2017 Nov 96 (45): e8505. Arellano Ana Lucía, Martin-Subero Marta, Monerris Mar, LLerena Adrián, Farré Magí, Montané E |
| Associations between ADRB1 and CYP2D6 gene polymorphisms and the response to ß-blocker therapy in hypertension. The Journal of international medical research 2015 Jun 43 (3): 424-34. Wu Dingchang, Li Ganyang, Deng Maoqing, Song Wei, Huang Xiaohua, Guo Xiaoru, Wu Zhengzheng, Wu Shiyang, Xu Jias |
| Impact of CYP2D6 polymorphisms on clinical efficacy and tolerability of metoprolol tartrate. Clinical pharmacology and therapeutics 2014 Aug 96 (2): 175-81. Hamadeh I S, Langaee T Y, Dwivedi R, Garcia S, Burkley B M, Skaar T C, Chapman A B, Gums J G, Turner S T, Gong Y, Cooper-DeHoff R M, Johnson J |
| Differences in genotype and allele frequency distributions of polymorphic drug metabolizing enzymes CYP2C19 and CYP2D6 in mainland Chinese Mongolian, Hui and Han populations. Journal of clinical pharmacy and therapeutics 2012 Jun 37 (3): 364-9. Yin S-J, Ni Y-B, Wang S-M, Wang X, Lou Y-Q, Zhang G |
| Carvedilol pharmacokinetics and pharmacodynamics in relation to CYP2D6 and ADRB pharmacogenetics. Pharmacogenomics 2011 Jun 12 (6): 783-95. Sehrt Daniel, Meineke Ingolf, Tzvetkov Mladen, Gültepe Senol, Brockmöller Jürg |
| Effects of commonly administered agents and genetics on nebivolol pharmacokinetics: drug-drug interaction studies. Journal of clinical pharmacology 2011 Apr 51 (4): 575-85. Lindamood Charles, Ortiz Stephan, Shaw Andrew, Rackley Russ, Gorski J Christoph |
| [Efficacy and safety of bisoprolol in pregnant women with chronic arterial hypertension do not depend on genetic CYP2D6 polymorphism]. Kardiologiia 2009 49 (7-8): 50-5. Brytkova Ia V, Ignat'ev I V, Kazakov R E, Sokova E A, Striuk R |
| [Genetic aspects of individual sensitivity to betaxolol in patients with arterial hypertension]. Kardiologiia 2008 48 (3): 20-6. Minushkina L O, Zate?shchikova A A, Zate?shchikov D A, Mankhaeva B B, Savel'eva E G, Kochkina M S, Brovkin A V, Nikitin A G, Nosikov V V, Sidorenko B |
| Association of CYP2D6 and ADRB1 genes with hypotensive and antichronotropic action of betaxolol in patients with arterial hypertension. Fundamental & clinical pharmacology 2007 Aug 21 (4): 437-43. Zateyshchikov Dmitry A, Minushkina Larissa O, Brovkin Alexey N, Savel'eva Ekaterina G, Zateyshchikova Anna A, Manchaeva Baira B, Nikitin Alexey G, Sidorenko Boris A, Nosikov Valery |
| Impact of CYP2D6 genotype on adverse effects during treatment with metoprolol: a prospective clinical study. Clinical pharmacology and therapeutics 2005 Oct 78 (4): 378-87. Fux Richard, Mörike Klaus, Pröhmer Anne M T, Delabar Ursula, Schwab Matthias, Schaeffeler Elke, Lorenz Gernot, Gleiter Christoph H, Eichelbaum Michel, Kivistö Kari |
| Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension. Clinical pharmacology and therapeutics 2004 Dec 76 (6): 536-44. Zineh Issam, Beitelshees Amber L, Gaedigk Andrea, Walker Joseph R, Pauly Daniel F, Eberst Kathleen, Leeder J Steven, Phillips Michael S, Gelfand Craig A, Johnson Julie |
| Impact of the ultrarapid metabolizer genotype of cytochrome P450 2D6 on metoprolol pharmacokinetics and pharmacodynamics. Clinical pharmacology and therapeutics 2004 Oct 76 (4): 302-12. Kirchheiner Julia, Heesch Claudia, Bauer Steffen, Meisel Christian, Seringer Angela, Goldammer Mark, Tzvetkov Mladen, Meineke Ingolf, Roots Ivar, Brockmöller Jürg |
| Effects of polymorphism of the beta(1) adrenoreceptor and CYP2D6 on the therapeutic effects of metoprolol. The Journal of international medical research 0 36 (6): 1354-62. Yuan H, Huang Z, Yang G, Lv H, Sang H, Yao |
- Page last reviewed:Feb 1, 2023
- Page last updated:Feb 03, 2023
- Content source: